HMGB1 enhances the AGE-induced expression of CTGF and TGF-β via RAGE-dependent signaling in renal tubular epithelial cells

American Journal of Nephrology

Volumn 41, Issue 3, 2015, Pages 257-266

  Cheng, Meichu ^a   Liu, Hong ^a   Zhang, Dongshan ^a   Liu, Yinghong ^a   Wang, Chang ^a   Liu, Fuyou ^a   Chen, Junxiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Advanced glycation end products; CTGF; High mobility group box 1; Renal epithelial cell; TGF

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SMOOTH MUSCLE ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; CTGF PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY TUBULE CELL; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL LINE; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; KIDNEY PROXIMAL TUBULE; METABOLISM;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; CELL LINE; CONNECTIVE TISSUE GROWTH FACTOR; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; KIDNEY TUBULES, PROXIMAL; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84928719808     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000381464     Document Type: Article

References (45)

1. Parving HH, Gall MA, Skøtt P, Jørgensen HE, Løkkegaard H, Jørgensen F, Nielsen B, Larsen S: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41: 758-762.
2. Pedro RA, Ramon SA, Marc BB, Juan FB, Isabel MM: Prevalence and relationship between diabetic retinopathy and nephropathy, and its risk factors in the North-East of Spain, a population-based study. Ophthalmic Epidemiol 2010; 17: 251-265.
3. Rosolowsky ET, Skupien J, Smiles AM, Niewczas M, Roshan B, Stanton R, Eckfeldt JH, Warram JH, Krolewski AS: Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011; 22: 545-553.
4. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ: Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005; 48: 1590-1603.
5. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ: Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidylcarbamate and application to nepsilon-carboxymethyl-lysine-and nepsilon-(1-carboxyethyl) lysine-modified albumin. Biochem J 2002; 364(Pt 1):1-14.
6. Goh SY, Cooper ME: Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-1152.
7. Raj DS, Choudhury D, Welbourne TC, Levi M: Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis 2000; 35: 365-380.
8. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842.
9. Oleniuc M, Schiller A, Secara I, Onofriescu M, Hogas S, Apetrii M, Siriopol D, Covic A: Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients. Int Urol Nephrol 2012; 44: 1441-1449.
10. Pollock CA, Poronnik P: Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Curr Opin Nephrol Hypertens 2007; 16: 359-364.
11. Caruso-Neves C, Pinheiro AA, Cai H, Souza-Menezes J, Guggino WB: PKB and megalin determine the survival or death of renal proximal tubule cells. Proc Natl Acad Sci USA 2006; 103: 18810-18815.
12. Twigg SM, Cao Z, MCLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME: Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002; 143: 4907-4915.
13. Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, Langham RG, Jerums G: Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 2003; 26: 2632-2636.
14. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR: Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008; 233: 4-11.
15. Zeisberg M, Kalluri R: Fibroblasts emerge via epithelial-mesenchymal transition in chronic kidney fibrosis. Front Biosci 2008; 13: 6991-6998.
16. Cheng M, Liu F, Peng Y, Chen J, Chen G, Xiao L, Liu H: Construction of a CTGF and RFPcoexpressed renal tubular epithelial cell and its application on evaluation of CTGF-specific siRNAs on epithelial-mesenchymal transition. Urology 2014; 83: 1443.e1-e8.
17. Conway B, Hughes J: Cellular orchestrators of renal fibrosis. QJM 2012; 105: 611-615.
18. Bell CW, Jiang W, Reich CF 3rd, Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291:C1318-C1325.
19. Landsman D, Bustin M: A signature for the HMG-1 box DNA-binding proteins. Bioessays 1993; 15: 539-546.
20. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005; 61: 1-9.
21. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487-496.
22. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006; 26: 174-179.
23. Harris HE, Raucci A: Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 2006; 7: 774-778.
24. Kim J, Sohn E, Kim CS, Jo K, Kim JS: The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am J Nephrol 2011; 33: 524-529.
25. Lin M, Yiu WH, Wu HJ, Chan LY, Leung JC, Au WS, Chan KW, Lai KN, Tang SC: Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 2012; 23: 86-102.
26. Lynch J, Nolan S, Slattery C, Feighery R, Ryan MP, McMorrow T: High-mobility group box protein 1: a novel mediator of inflammatoryinduced renal epithelial-mesenchymal transition. Am J Nephrol 2010; 32: 590-602.
27. Chuang PY, Menon MC, He JC: Molecular targets for treatment of kidney fibrosis. J Mol Med (Berl) 2013; 91: 549-559.
28. Hammes HP, Wellensiek B, Klöting I, Sickel E, Bretzel RG, Brownlee M: The relationship of glycaemic level to advanced glycation endproduct (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster. Diabetologia 1998; 41: 165-170.
29. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
30. Twigg SM, Joly AH, Chen MM, Tsubaki J, Kim HS, Hwa V, Oh Y, Rosenfeld RG: Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation endproducts in human dermal fibroblasts. Endocrinology 2002; 143: 1260-1269.
31. Huang K, Huang J, Xie X, Wang S, Chen C, Shen X, Liu P, Huang H: Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-?1 by activating the Nrf2/ARE pathway in glomerular mesangial cells. Free Radic Biol Med 2013; 65: 528-540.
32. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-1666.
33. Thomas MC, Forbes JM, Cooper ME: Advanced glycation end products and diabetic nephropathy. Am J Ther 2005; 12: 562-572.
34. Forbes JM, Cooper ME, Oldfield MD, Thomas MC: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003; 14:S254-S258.
35. Wahab NA, Yevdokimova N, Weston BS, Roberts T, Li XJ, Brinkman H, Mason RM: Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 2001; 359(Pt 1):77-87.
36. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11: 25-38.
37. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M: Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003; 63: 464-473.
38. Osicka TM, Yu Y, Panagiotopoulos S, Clavant SP, Kiriazis Z, Pike RN, Pratt LM, Russo LM, Kemp BE, Comper WD, Jerums G: Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 2000; 49: 87-93.
39. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001; 108: 1853-1863.
40. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15004.
41. Ramasamy R, Yan SF, Schmidt AM: The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol 2012; 57: 160-167.
42. Xie J, Méndez JD, Méndez-Valenzuela V, Aguilar-Hernández MM: Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal 2013; 25: 2185-2197.
43. Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease: advanced glycation endproducts and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008; 4: 285-293.
44. Li JH, Wang W, Huang XR, Oldfield M, Schmidt AM, Cooper ME, Lan HY: Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 2004; 164: 1389-1397.
45. Wynn TA: Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-529.